SCHEMBL2492405

SCHEMBL2492405

COc1cc(NC(C)=O)ccc1C(=O)CCl

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 3/20 0.54
TP53 P04637 1/20 0.54
HIF1A Q16665 1/20 0.54
SMN1; SMN2 Q16637 3/20 0.50
POLB P06746 2/20 0.49
MAPK1 P28482 2/20 0.48
RORC P51449 1/20 0.47
LMNA P02545 1/20 0.46
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
BRAF P15056 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MCHR1 Q99705 3/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10757306 0.85 TDP1 (0.55) TDP1ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL5208087 0.85 TDP1 (0.55) TDP1ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL27831799 0.85 HPGD (0.53) ALDH1A1SMN1; SMN2MAPK1HTTKMT2A
SCHEMBL1493992 0.83 MAPK1 (0.57) TDP1ALDH1A1TP53SMN1; SMN2POLB
SCHEMBL28147929 0.82 LMNA (0.43) TDP1ALDH1A1SMN1; SMN2LMNAKMT2A
SCHEMBL2555975 0.81 TDP1 (0.73) TDP1ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL1162352 0.81 TDP1 (0.56) TDP1ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL14421098 0.80 TDP1 (0.55) TDP1ALDH1A1SMN1; SMN2POLBMAPK1
SCHEMBL8307201 0.80 POLB (0.74) TDP1ALDH1A1TP53HIF1ASMN1; SMN2
SCHEMBL12970763 0.80 TDP1 (0.55) TDP1ALDH1A1SMN1; SMN2POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022008678-A2 AURONE DERIVATIVES AND USES THEREOF FOR CONTROLLING BACTERIA AND/OR FUNGI UNIVERSITE D'AIX-MARSEILLE (FR) 2022-01-13 WO disclosed
EP-1751127-B1 NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF INTERMED DISCOVERY GMBH (DE) 2012-07-11 EP disclosed
US-8030347-B2 Cylopenta[b]benzofuran derivatives and the utilization thereof BAYER HEALTHCARE AG (DE) 2011-10-04 US disclosed
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof BAYER HEALTHCARE AG (DE) 2009-01-15 US disclosed
EP-1751127-A2 NOVEL CYLOPENTA¬B|BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF Bayer HealthCare AG (DE) 2007-02-14 EP disclosed
WO-2005113529-A2 NOVEL CYLOPENTA[B]BENZOFURAN DERIVATIVES AND THE UTILIZATION THEREOF BAYER HEALTHCARE AG (DE) 2005-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018113-A1 Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof FKBP1A, FKBP2, FKBP1B TDP1 2358/4885ALDH1A1 3777/4885TP53 1669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.